Роль оксиду азоту в патогенезі та лікуванні захворювань серцево-судинної системи (огляд літератури)

Автор(и)

  • С. Білецький д-р мед. наук, професор кафедри сімейної медицини Буковинського державного медичного університету, м. Чернівці

DOI:

https://doi.org/10.24061/2413-0737.XXV.2.98.2021.21

Ключові слова:

ендотелій; оксид азоту (NO); L-аргінін; гіпертонічна хвороба; ішемічна хвороба серця

Анотація

Наводяться дані літератури про роль ендотелію та оксиду азоту в патогенезі серцево-судинних захворювань, застосування L-арініну у складі комплексної терапії хворих на артеріальну гіпертензію (АГ) та ішемічної хвороби серця (ІХС).
Мета роботи - систематизувати сучасні дані літератури про роль ендотелію та оксиду азоту в патогенезі серцево-судинних захворювань, клінічний досвід використання L-аргініну у хворих на АГ та ІХС.
Висновок. На сьогоднішній день сформульована концепція ендотеліальної дисфункції з недостатнім виробленням оксиду азоту як центральної ланки патогенезу АГ і ІХС. Компенсація дефіциту оксиду азоту при захворюваннях серцево-судинної системи можлива за допомогою донаторів NO.

Посилання

Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009;32(2):S314-21. DOI: 10.2337/dc09-S330.

Bulaeva NI, Golukhova EZ. Endotelial'naya disfunktsiya i oksidativnyy stress: rol' v razvitii kardiovaskulyarnoy patologii [Endothelial dysfunction and oxidative stress: a role in the development of cardiovascular pathology]. Kreativnaya kardiologiya. 2013;1:14-22. (in Russian).

Vozna KhI, Moskaliuk VD, Sorokhan VD. Endotelii: funktsional'ni vlastyvosti ta yoho dysfunktsiia (ohliad literatury z materialamy vlasnykh doslidzhen') [Endothelium: functional properties and its dysfunction (literature review with materials of own researches)]. Klinichna ta eksperymental'na patolohiia. 2015;14(1):209-14. (in Ukrainian).

Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373-6.

McRae MP. Therapeutic benefits of l-Arginine: an umbrella review of meta-analyses. J Chiropr Med. 2016;15(3):184-9. DOI: 10.1016/j.jcm.2016.06.002.

Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci. 2009;14:1-18. DOI: 10.2741/3228.

Böger RH. The pharmacodynamics of L-arginine. J Nutr. 2007;137(6):1650S-55S. DOI: 10.1093/jn/137.6.1650S.

Morris SM Jr. Arginine metabolism revisited. J Nutr. 2016;146(12):2579S-86S.

Nishimoto M, Mizuno R, Fujita T, Isshiki M. Stromal interaction molecule 1 modulates blood pressure via NO production in vascular endothelial cells. Hypertens Res. 2018;41(7):506-14. DOI: 10.1038/s41440-018-0045-1.

Heffernan KS, Fahs CA, Ranadive SM, Patvardhan EA. L-arginine as a nutritional prophylaxis against vascular endothelial dysfunction with aging. J Cardiovasc Pharmacol Ther. 2010;15(1):17-23. DOI: 10.1177/1074248409354599.

Litvyakov AM, Sergievich AV. Arginin-zavisimye mekhanizmy v patogeneze ateroskleroza [Arginine-dependent mechanisms in the pathogenesis of atherosclerosis]. Vestsi NAN Belarusi. 2013;1:103-12. (in Russian).

Chen M, Yi B, Zhu N, Wei X, Zhang GX, Huang S, et al. Pim1 kinase promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase at Ser-633. Cardiovasc Res. 2016;109(1):141-50. DOI: 10.1093/cvr/cvv250.

Sokolova LK, Pushkar'ov VM, Tron'ko MD. L-arhinin u normi ta patolohii [L-arginine is normal and pathological]. Endokrynolohiia. 2019;24(4):373-85. (in Ukrainian).

Sudar-Milovanovic E, Obradovic M, Jovanovic A, Zaric B, Zafirovic S, Panic A, et al. Benefits of L-arginine on cardiovascular system. Mini Rev Med Chem. 2016;16(2):94-103. DOI: 10.2174/1389557515666151016125826.

Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res. 2013;98(3):334-43. DOI: 10.1093/cvr/cvt036.

Krause M, Rodrigues-Krause J, O’Hagan C, De Vito G, Boreham C, Susta D, et al. Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study. Metabolism. 2012;61(11):1528-37.

Matsuzawa Y, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Secondary prevention strategy of cardiovascular disease using endothelial function testing. Circ J. 2015;79(4):685-94. DOI: 10.1253/circj.CJ-15-0068.

Zharinova VYu, Parasyuk EI, Samots' IA, Benkovskaya NN. Vozmozhnosti povysheniya effektivnosti antigipertenzivnoy terapii: rol' donatorov oksida azota [Possibilities of increasing the effectiveness of antihypertensive therapy: the role of nitric oxide donors]. Zdorov’ia Ukrainy. 2016;1:45-6. (in Russian).

Jensen HA, Mehta JL. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Exp Rev Cardiovasc Ther. 2016;14(9):1021-33.

Dobutovic B, Smiljanic K, Soskic S, Düngen H-D, Isenovic ER. Nitric oxide and its role in cardiovascular diseases. The Open Nitric Oxide J. 2011;3:65-71.

Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder. Am J Physiol Heart Circ Physiol. 2006;291(3):H985-1002. DOI: 10.1152/ajpheart.00292.2006.

Katerenchuk IP. Shliakhy medykamentoznoi korektsii NO-zalezhnoi kardiovaskuliarnoi patolohii v patsiientiv litn'oho y pokhyloho viku [Ways of drug correction of NO-dependent cardiovascular pathology in elderly and elderly patients]. Praktykuiuchyi likar. 2016;5(3):38-44. (in Ukrainian).

Torregrossa AC, Aranke M, Bryan NS. Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly. J Geriatr Cardiol. 2011;8(4):230-42.

Maksiv KhIa, Maruschak MI. Patohenez arterial'noi hipertenzii: rol' okysniuval'nykh protsesiv [Pathogenesis of arterial hypertension: the role of oxidative processes]. Visnyk medychnykh i biolohichnykh doslidzhen'. 2020;2:81-7. (in Ukrainian).

Get'man OI, Girin VV. Dinamika pokazateley soderzhaniya oksida azota i produktov perekisnogo okisleniya lipidov u bol'nykh s arterial'noy gipertenziey [Dynamics of indicators of the content of nitric oxide and lipid peroxidation products in patients with arterial hypertension]. Ukrainskiy terapevticheskiy zhurnal. 2011;3:89-92. (in Russian).

Garcia VP, Rocha HNM, Silva GM, Amaral TAG, Secher NH, Nóbrega ACL, et al. Exogenous L-arginine reduces matrix metalloproteinase-2 and-9 activities and oxidative stress in patients with hypertension. Life Sci. 2016;157:125-30. DOI: 10.1016/j.lfs.2016.06.006.

Asadi S, Mozaffari-Khosravi H, Naghizade MM, Nadjarzadeh A. The effect of L-arginine supplementation on blood pressure in patients with type 2 diabetes: a double-blind randomized clinical trial. Journal of Nutrition and Food Security. 2016;1(1):17-27.

Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos M, Kotsis V, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. 2002;86(2-3):317-23.

Jabecka A, Ast J, Bogdaski P, Drozdowski M, Pawlak-Lemaska K, Cielewicz AR, et al. Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citrulline, L-arginine and antioxidant status. Eur Rev Med Pharmacol Sci. 2012;16(12):1665-74.

Palloshi A, Fragasso G, Piatti P, Monti LD, Setola E, Valsecchi G, et al. Links effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol. 2004;93(7):933-5. DOI: 10.1016/j.amjcard.2003.12.040.

Bai Y, Sun L, Yang T, Sun K, Chen J, Hui R. Increase in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2009;89(1):77-84. DOI: 10.3945/ajcn.2008.26544.

Slobods'kyi VA. Dosvid zastosuvannia preparatu Tivortin aspartat pry likuvanni patsiientiv zi stabil'noiu stenokardiieiu napruzhennia [Experience in the use of the drug Tivortin aspartate in the treatment of patients with stable angina pectoris]. Ukrains'kyi medychnyi chasopys. 2009;5:40-3. (in Ukrainian).

Vorob'eva OA. Terapevticheskie effekty metabolitotropnogo kardioprotektora, soderzhashchego L-arginin i inozin, u bol'nykh pozhilogo i starcheskogo vozrasta s IBS [Therapeutic Effects of a Metabolithotropic Cardioprotector Containing L-Arginine and Inosine in Elderly and Senile Patients with IHD]. Patolohiia. 2012;2:98-101. (in Russian).

Yin W-H, Chen Y-W, Tsai Ch, Chiang M-C, Young MS, Lin SJ. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr. 2005;24(6):988-97.

Zozuliak NV. Protektsiia endoteliiu sudyn u khvorykh na stabil'nu stenokardiiu III FK iz suputn'oiu arterial'noiu hipertenziieiu shliakhom zastosuvannia donatora oksydu azotu L-arhininu (Tivortin) ta metabolitotropnoho preparatu Meksykor [Protection of vascular endothelium in patients with stable angina III FC with concomitant hypertension through the use of nitric oxide donor L-arginine (Tivortin) and metabolite drug Mexico]. Halyts'kyi likars'kyi visnyk. 2012;19(4):34-6. (in Ukrainian).

Stepanov YuM, Kononov IN, Zhurbina AI, Filippova AYu. Arginin v meditsinskoy praktike (obzor literatury) [Arginine in medical practice (literature review)]. Zhurnal AMN Ukrainy. 2004;10(1):340-52. (in Russian).

Lutai MI, Buhaienko VV, Moiseienko OI, Mushtenko LO, Slobods'kyi VA. Znachennia L-arhininu v likuvanni khvorykh iz sertsevo-sudynnoiu patolohiieiu [The value of L-arginine in the treatment of patients with cardiovascular pathology]. Ukrains'kyi kardiolohichnyi zhurnal. 2011;4:96-107. (in Ukrainian).

##submission.downloads##

Опубліковано

2021-08-26

Номер

Розділ

НАУКОВІ ОГЛЯДИ